Your browser doesn't support javascript.
loading
Reduction of Drug-Drug Interaction Risk; CDC Guidelines Influence on Opiate Benzodiazepine Prescribing.
Pesce, Amadeo; Thomas, Richard; Krock, Kevin; Tran, Keith; Ackerman, Gregory; Nickley, Joyce.
Afiliação
  • Pesce A; Precision Diagnostics, San Diego, CA, USA Amadeo.pesce@precisiondxlab.com.
  • Thomas R; Precision Diagnostics, San Diego, CA, USA.
  • Krock K; Precision Diagnostics, San Diego, CA, USA.
  • Tran K; Precision Diagnostics, San Diego, CA, USA.
  • Ackerman G; Precision Diagnostics, San Diego, CA, USA.
  • Nickley J; Precision Diagnostics, San Diego, CA, USA.
Ann Clin Lab Sci ; 50(3): 321-326, 2020 May.
Article em En | MEDLINE | ID: mdl-32581020
ABSTRACT
We examined the results of 1.3 million drug tests performed on patients being monitored for compliance with pain medications and substance abuse rehabilitation to determine if the 2016 CDC prescribing guidelines had any impact on opiate benzodiazepine use. We observed that the combination of the opiate drugs morphine, oxycodone, and hydrocodone with the benzodiazepine metabolites oxazepam, alphahydroxyalprazolam, and 7-aminoclonazepam showed many patients were on a combination of these drugs. This ranged from approximately 9 to 16%. There was considerable variability between opiate drug pairs, but there was a general trend to fewer patients on the combination of opiate-benzodiazepine over the 2016 to 2019 time frame.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Fidelidade a Diretrizes / Quimioterapia Combinada / Transtornos Relacionados ao Uso de Opioides Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Fidelidade a Diretrizes / Quimioterapia Combinada / Transtornos Relacionados ao Uso de Opioides Idioma: En Ano de publicação: 2020 Tipo de documento: Article